Company research
Jaguar Health, Inc.
CIK 1585608Updated Nov 11, 2026
SecurityJAGX · NASDAQ · equity
Name history
Jaguar Animal Health, Inc. · through Jul 31, 2017
JAGX price & chart
Loading TradingView…
NASDAQ:JAGX on TradingView ↗About the company
Jaguar was founded in San Francisco, California, as a Delaware corporation on June 6, 2013 (“inception”). The Company was a majority-owned subsidiary of Napo until the close of the Company’s initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class prescription and non-prescription products for companion animals. On July 31, 2017, Jaguar completed a merger with Napo pursuant to the Agreement and Plan of Merger dated March 31, 2017, by and among Jaguar, Napo, Napo Acquisition Corporation (“Merger Sub”), and Napo’s representative (the “Merger Agreement”). In accordance with the terms of the Merger Agreement, upon the completion of the merger, Merger Sub merged with and into Napo, with Napo surviving as the wholly owned subsidiary (the “Merger” or “Napo Merger”). Immediately following the Merger, Jaguar changed its name from “Jaguar Animal Health, Inc.” to “Jaguar Health, Inc.” Napo now operates as a wholly owned subsidiary of Jaguar focused on human health, including the ongoing development of crofelemer and commercialization of Mytesi.
In the news
No coverage from other publishers is available.
Recent filings
424B5 filing
424B3 filing
Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Items 5.07, 7.01, 9.01
EFFECT filing
S-3/A filing
Show 5 more recent filings
Other Events
Items 8.01
DEFA14A filing
Other Events
Items 8.01
S-3 filing
DEF 14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 49,472,000Source | 58,466,000Source | 34,194,000Source | 48,268,000Source | 61,459,000Source | 37,434,000Source | 51,460,000Source | 55,389,000Source | 38,323,000Source | 53,425,000Source | 50,763,000Source | 47,452,000Source |
| Property, Plant and Equipment, NetUSD | 483,000Source | 476,000Source | 417,000Source | 441,000Source | 488,000Source | 423,000Source | 452,000Source | 484,000Source | 463,000Source | 464,000Source | 496,000Source | 557,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 17,285,000Source | 18,947,000Source | 15,086,000Source | 17,545,000Source | 19,408,000Source | 15,553,000Source | 18,011,000Source | 19,627,000Source | 16,021,000Source | 18,479,000Source | 20,116,000Source | 22,439,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,527,000Source | 13,269,000Source | 3,788,000Source | 2,207,000Source | 16,049,000Source | 7,278,000Source | 5,690,000Source | 11,671,000Source | 968,000Source | 8,002,000Source | 6,469,000Source | 5,469,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,437,000Source | 1,249,000Source | 8,000Source | 1,173,000Source | 1,299,000Source | 68,000Source | 1,223,000Source | 1,512,000Source | 1,521,000Source | 1,527,000Source | 1,967,000Source | 1,879,000Source |
| Inventory, NetUSD | 10,628,000Source | 9,674,000Source | 7,316,000Source | 10,719,000Source | 9,556,000Source | 7,819,000Source | 10,555,000Source | 9,020,000Source | 8,599,000Source | 10,345,000Source | 9,189,000Source | 7,024,000Source |
| Assets, CurrentUSD | 29,402,000Source | 36,643,000Source | 17,533,000Source | 27,903,000Source | 40,111,000Source | 20,210,000Source | 30,439,000Source | 33,714,000Source | 20,345,000Source | 32,198,000Source | 27,963,000Source | 22,321,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,743,000Source | 12,394,000Source | 3,429,000Source | 13,661,000Source | 13,142,000Source | 2,047,000Source | 12,805,000Source | 11,309,000Source | 2,216,000Source | 12,204,000Source | 10,121,000Source | 7,361,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,062,000Source | 1,057,000Source | 1,011,000Source | 1,138,000Source | 1,176,000Source | 1,079,000Source | 1,211,000Source | 1,289,000Source | 1,000,000Source | 936,000Source | 1,176,000Source | 1,140,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 45,113,000Source | 42,883,000Source | 29,273,000Source | 41,388,000Source | 42,396,000Source | 53,186,000Source | 48,145,000Source | 41,086,000Source | 57,011,000Source | 44,446,000Source | 45,866,000Source | 48,808,000Source |
| Stockholders’ equity: | ||||||||||||
| Retained Earnings (Accumulated Deficit)USD | -376,855,000Source | -336,561,000Source | -403,749,000Source | -367,353,000Source | -326,707,000Source | -391,067,000Source | -356,946,000Source | -317,215,000Source | -399,916,000Source | -346,482,000Source | -308,248,000Source | -266,948,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -839,000Source | -687,000Source | -1,241,000Source | -719,000Source | -542,000Source | -1,242,000Source | -700,000Source | -461,000Source | -833,000Source | -467,000Source | -652,000Source | -680,000Source |
| Additional Paid in Capital, Common StockUSD | 380,836,000Source | 350,859,000Source | 411,605,000Source | 373,575,000Source | 344,155,000Source | 378,130,000Source | 359,428,000Source | 329,647,000Source | 380,974,000Source | 354,234,000Source | 313,854,000Source | 266,971,000Source |
| Liabilities and EquityUSD | 49,472,000Source | 58,466,000Source | 34,194,000Source | 48,268,000Source | 61,459,000Source | 37,434,000Source | 51,460,000Source | 55,389,000Source | 38,323,000Source | 53,425,000Source | 50,763,000Source | 47,452,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 36,122,000Source | 19,874,000Source | 25,380,000Source | 29,218,000Source | 19,133,000Source | 40,686,000Source | 28,208,000Source | 17,814,000Source | 40,654,000Source | 19,704,000Source | 13,987,000Source | 30,339,000Source |
| Operating Lease, Liability, CurrentUSD | 226,000Source | 368,000Source | 219,000Source | 256,000Source | 416,000Source | 261,000Source | 273,000Source | 469,000Source | 192,000Source | 299,000Source | 348,000Source | 483,000Source |
| Accounts Payable, CurrentUSD | 8,443,000Source | 4,552,000Source | 4,793,000Source | 6,617,000Source | 4,093,000Source | 4,957,000Source | 7,028,000Source | 3,320,000Source | 8,686,000Source | 5,286,000Source | 4,974,000Source | 5,808,000Source |
| Operating Lease, Liability, NoncurrentUSD | 918,000Source | 754,000Source | 873,000Source | 960,000Source | 812,000Source | 898,000Source | 998,000Source | 873,000Source | 892,000Source | 686,000Source | 886,000Source | 725,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,268,000Source | -514,000Source | -1,694,000Source | -1,108,000Source | -328,000Source | -1,574,000Source | -952,000Source | -180,000Source | -1,399,000Source | -791,000Source | -64,000Source | -699,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,175,000Source | 3,297,000Source | 4,712,000Source | 3,603,000Source | 3,339,000Source | 3,751,000Source | 2,101,000Source | 3,461,000Source | 4,166,000Source | 1,911,000Source | 3,798,000Source | 8,165,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -9,648,000Source | -10,021,000Source | -12,802,000Source | -10,560,000Source | 8,723,000Source | -10,596,000Source | -53,997,000Source | -39,251,000Source | -41,901,000Source | -48,395,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 473,000Source | 479,000Source | 1,913,000Source | 1,900,000Source | 2,013,000Source | 1,981,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 155,000Source | 301,000Source | 831,000Source | 1,641,000Source | 2,112,000Source | 3,318,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -1,453,000Source | -304,000Source | -6,000Source | -440,000Source | 88,000Source | 170,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -780,000Source | 209,000Source | 254,000Source | 1,156,000Source | 2,165,000Source | 2,124,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -3,755,000Source | 1,723,000Source | 3,346,000Source | 328,000Source | -855,000Source | 902,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 8,830,000Source | -7,314,000Source | -23,686,000Source | -29,384,000Source | -33,242,000Source | -33,104,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -41,000Source | -231,000Source | — | -1,675,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 16,000Source | — | 77,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -6,615,000Source | 4,966,000Source | 23,670,000Source | 31,202,000Source | 34,227,000Source | 23,181,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 2,232,000Source | -2,312,000Source | -170,000Source | 1,533,000Source | 1,000,000Source | -11,582,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,527,000Source | 13,269,000Source | 6,590,000Source | 2,207,000Source | 10,064,000Source | 5,690,000Source | 7,832,000Source | 8,002,000Source | 6,469,000Source | 5,469,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 119,000Source | 6,000Source | 22,000Source | 14,000Source | 35,000Source | 23,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 135,000Source | 310,000Source | 171,000Source | 279,000Source | 155,000Source | 301,000Source | 831,000Source | 1,641,000Source | 2,112,000Source | 3,318,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | 153,000Source | 274,000Source | 13,206,000Source | 11,758,000Source |
| Amortization of Intangible AssetsUSD | — | — | 468,000Source | 461,000Source | 467,000Source | 467,000Source | 467,000Source | 467,000Source | 1,900,000Source | 1,900,000Source | 2,000,000Source | 1,800,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | -3,504,000Source | -1,822,000Source | -628,000Source | 0Source | -1,799,000Source | 1,245,000Source | 3,697,000Source | -2,187,000Source |
| General and Administrative ExpenseUSD | — | — | 4,134,000Source | 3,776,000Source | 4,450,000Source | 4,727,000Source | 4,108,000Source | 4,897,000Source | 18,644,000Source | 16,331,000Source | 16,588,000Source | 17,868,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 800,000Source | — | 371,000Source | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | — | 0Source | 0Source | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | -9,000Source | -33,000Source | -162,000Source | -138,000Source | -51,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 2,000,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -9,502,000Source | -9,854,000Source | — | -10,407,000Source | — | -10,464,000Source | -53,575,000Source | -39,250Source | -41,300,000Source | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -146,000Source | -167,000Source | -120,000Source | -153,000Source | -126,000Source | -132,000Source | -563,000Source | -759,000Source | -601,000Source | -941,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,502,000Source | -9,854,000Source | -12,701,000Source | -10,407,000Source | -7,015,000Source | -10,464,000Source | -53,575,000Source | -38,492,000Source | -41,300,000Source | -47,454,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -94,000Source | 168,000Source | 378,000Source | 322,000Source | 205,000Source | 112,000Source | 43,000Source | 51,000Source | 200,000Source | 950,000Source |
| Proceeds from (Payments to) Noncontrolling InterestsUSD | — | — | — | — | — | — | — | — | — | — | 1,233,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,083,000Source | 3,108,000Source | 1,225,000Source | 2,979,000Source | 20,272,000Source | 2,214,000Source | 11,511,000Source | 11,689,000Source | — | 11,956,000Source |
| Cost of RevenueUSD | — | — | — | 541,000Source | 1,031,000Source | 97,000Source | 1,158,000Source | 515,000Source | 97,000Source | 1,955,000Source | 2,037,000Source | 2,019,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -7,238,000Source | -7,262,000Source | -7,597,000Source | -8,007,000Source | 10,182,000Source | -9,421,000Source | -45,908,000Source | -30,831,000Source | -34,291,000Source | -34,415,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -94,000Source | 168,000Source | 378,000Source | 322,000Source | 205,000Source | 112,000Source | 43,000Source | 51,000Source | 200,000Source | 950,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -9,648,000Source | -10,021,000Source | -12,802,000Source | -10,560,000Source | 8,723,000Source | -10,596,000Source | -53,997,000Source | -39,251,000Source | -41,901,000Source | -48,395,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -146,000Source | -167,000Source | -120,000Source | -153,000Source | -126,000Source | -132,000Source | -563,000Source | -759,000Source | -601,000Source | -941,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -9,502,000Source | -9,854,000Source | — | -10,407,000Source | — | -10,464,000Source | -53,575,000Source | -39,250Source | -41,300,000Source | — |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -15.7Source | -358.94Source | -13.6Source | -584.45Source | -22.97Source | -130.69Source | -1.79Source | -36.18Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -15.7Source | -358.94Source | -13.6Source | -584.45Source | -22.97Source | -130.69Source | -1.79Source | -36.18Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 809,122Source | 28,994Source | 515,788Source | 17,904Source | 2,332,401Source | 294,534Source | 23,068,423Source | 1,311,519Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 809,122Source | 28,994Source | 515,788Source | 17,904Source | 2,332,401Source | 294,534Source | 23,068,423Source | 1,311,519Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 468,000Source | 461,000Source | 467,000Source | 467,000Source | 467,000Source | 467,000Source | 1,900,000Source | 1,900,000Source | 2,000,000Source | 1,800,000Source |
| Costs and ExpensesUSD | — | — | 10,321,000Source | 10,370,000Source | 8,822,000Source | 10,986,000Source | 10,090,000Source | 11,635,000Source | 57,419,000Source | 42,520,000Source | 44,052,000Source | 46,371,000Source |
| General and Administrative ExpenseUSD | — | — | 4,134,000Source | 3,776,000Source | 4,450,000Source | 4,727,000Source | 4,108,000Source | 4,897,000Source | 18,644,000Source | 16,331,000Source | 16,588,000Source | 17,868,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -48,800,000Source | -34,300,000Source | -35,600,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | -9,000Source | -33,000Source | -162,000Source | -138,000Source | -51,000Source | — |
| Interest ExpenseUSD | — | — | 6,000Source | -162,000Source | 161,000Source | -15,000Source | 699,000Source | -56,000Source | 67,000Source | 231,000Source | 6,382,000Source | 12,723,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,502,000Source | -9,854,000Source | -12,701,000Source | -10,407,000Source | -7,015,000Source | -10,464,000Source | -53,575,000Source | -38,492,000Source | -41,300,000Source | -47,454,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | 8,000Source | 0Source | 6,063,000Source | 0Source | 141,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 3,658,000Source | 4,043,000Source | 3,336,000Source | 3,265,000Source | 3,928,000Source | 3,730,000Source | 24,966,000Source | 16,542,000Source | 18,596,000Source | 17,647,000Source |
| Selling and Marketing ExpenseUSD | — | — | 1,997,000Source | 2,010,000Source | 5,000Source | 2,467,000Source | 896,000Source | 2,493,000Source | 9,235,000Source | 7,692,000Source | 6,460,000Source | 8,837,000Source |
| Preferred Stock Dividends and Other Adjustments | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-299584
Registration 333-297489
Registration 333-297488
Filing attachments
d191844dex991.htm · 8-K · 2026-11-06
Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders San Francisco, CA (November 6, 2026): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced the voting results of the Company’s November 6, 2026 Special Meeting of Stockholders (the “Special Meeting”). Six proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company’s d…
Read attachment ↗d183888dex41.htm · 8-K · 2026-10-05
Exhibit 4.1 GLOBAL AMENDMENT #6 This Global Amendment #6 (this “Amendment”) is entered into as of September 30, 2026 by and between Uptown Capital, LLC, a Utah limited liability company (f/k/a Irving Park Capital, LLC) (“Investor”), and Jaguar Health, Inc. a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Royalty Interest (as defined below). A. Company previously sold and issued to Investor that certain…
Read attachment ↗d183888dex42.htm · 8-K · 2026-10-05
Exhibit 4.2 GLOBAL AMENDMENT #6 This Global Amendment #6 (this “Amendment”) is entered into as of September 30, 2026 by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Royalty Interest (as defined below). A. Company previously sold and issued to Investor that certain Royalty Interest dated A…
Read attachment ↗d183888dex43.htm · 8-K · 2026-10-05
Exhibit 4.3 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of September 30, 2026, by and among Streeterville Capital, LLC, a Utah limited liability company (“Lender”), Jaguar Health, Inc., a Delaware corporation (“Company”), and Napo Pharmaceuticals, Inc., a Delaware corporation (“Napo”, and together with Company, “Borrower”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such te…
Read attachment ↗d183888dex991.htm · 8-K · 2026-10-05
Exhibit 99.1 Jaguar Health Announces a Special Stock Dividend Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / October 2, 2026 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or “the Company”) today announced that its Board of Directors has declared a special stock dividend (the “Special Stock Dividend”) to holders of Jaguar Common Stock and certain outstanding warrants as of record on October …
Read attachment ↗d183888dex992.htm · 8-K · 2026-10-05
Exhibit 99.2 Risk Factors Unless the context otherwise requires, references herein to “Jaguar,” the “Company,” “we,” “us,” and “our” refer to Jaguar Health, Inc. Terms used but not defined herein have the respective meanings set forth in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on October 5, 2026 (the “Current Report”). The risk factors discussed below contain description of the terms and conditions of the form of the Certificate of Designation of P…
Read attachment ↗